Jacquelyn Kissel

Jacquelyn Kissel

Auto-generated profile, based on publicly available information

Jacquelyn Kissel

Equitas Health, Columbus, OH

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2023 in Journal of the American Pharmacists Association
Verified
Journal Article
Closed access
VPVictor Perez
Victor Perez
RLRebecca Lahrman
Rebecca Lahrman
JKJacquelyn Kissel
Jacquelyn Kissel
TVTeagan Vaughn
Teagan Vaughn
JLJunan Li
Junan Li
LHLaura E. Hall
Laura E. Hall

8 December 2025 in Journal of the American Pharmacists Association
Verified
Journal Article
Closed access
LHLevi Hill
Levi Hill
JKJacquelyn Kissel
Jacquelyn Kissel
PPPhil Pauvlinch
Phil Pauvlinch
JSJennifer Seifert
Jennifer Seifert
RLRebecca Lahrman
Rebecca Lahrman

10 June 2025 in Journal of the American Pharmacists Association
Verified
Journal Article
Closed access
GHGrace Havens
Grace Havens
RLRebecca Lahrman
Rebecca Lahrman
JKJacquelyn Kissel
Jacquelyn Kissel
TVTeagan Vaughn
Teagan Vaughn
JLJunan Li
Junan Li
LHLaura E. Hall
Laura E. Hall

26 May 2026 in Journal of the American Pharmacists Association
Verified
Journal Article
Open access
SBShreya Barde
Shreya Barde
RLRebecca Lahrman
Rebecca Lahrman
JKJacquelyn Kissel
Jacquelyn Kissel
TVTeagan Vaughn
Teagan Vaughn
ACAlvin Choy
Alvin Choy
LHLaura E. Hall
Laura E. Hall
Ending the HIV epidemic remains a global public health priority, with ongoing efforts to minimize infections by 2030. Pharmacists play a crucial role in managing HIV prevention (PrEP) with cabotegravir (CAB) and treatment with cabotegravir/rilpivirine (CAB/RPV) by optimizing antiretroviral (ARV) therapies and adherence. An Ohio-based not-for-profit organization with healthcare clinics and in-house pharmacies has implemented a pharmacist-led program managing long-acting injectable antiretrovirals (LAI-ARVs) using collaborative practice agreements (CPAs) with clinic providers. The innovative workflow addresses LAI-ARV implementation challenges and leverages pharmacist expertise to optimize patient care. The primary objective of this study is to evaluate the role of ambulatory care pharmacists in a LAI-ARV program by describing approval/denial to the program after primary care provider (PCP) referral. The secondary objective is to quantify the ambulatory care pharmacist interventions during HIV treatment/PrEP LAI program Referral Review. A CPA was developed at five clinic locations to implement a pharmacist-led LAI-ARV program for the treatment and prevention of HIV. Referral data were retrospectively reviewed to assess approval or denial of potential injectable candidates and to describe pharmacist interventions. Out of the 1103 referrals reviewed, 893 were approved and 210 were denied. CAB/RPV referrals had more denials due to safety and efficacy concerns. Of the 893 approved referrals, 264 required at least one clinical intervention to address logistic, safety and efficacy considerations before initiation of LAI-ARV. Pharmacist interventions often address safety concerns such as hepatitis B virus (HBV) risk, drug interactions, and risk of in adherence to appointments. This study highlights the impact of pharmacist-led processes in optimizing LAI-ARV therapy through patient-specific evaluation and clinical interventions. Pharmacist involvement ensures appropriate candidate selection, safe therapy implementation, and supports the broader public health efforts to reduce HIV transmission and end the HIV epidemic.